Skip to Main Content

Author Details

Antje-Christine Walz
Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd.
2002
30
13
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37002450Correction: Preclinical In Vivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 Tâ¿¿Cell Bispecific in Combination with Antiâ¿¿PDâ¿¿L1.AAPS J2023
37603766Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies.Proc Natl Acad Sci U S A2023
37216399Filter inference: A scalable nonlinear mixed effects inference approach for snapshot time series data.PLoS Comput Biol2023
35189161Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs.Pharmacol Ther2022
35508177Patient-derived micro-organospheres enable clinical precision oncology.Cell Stem Cell2022
35779780Passive immunization against COVID-19 by anti-SARS-CoV-2 spike IgG in commercially available immunoglobulin preparations in severe antibody deficiency.J Allergy Clin Immunol Pract2022
36207642Preclinical InVivo Data Integrated in a Modeling Network Informs a Refined Clinical Strategy for a CD3 T-Cell Bispecific in Combination with Anti-PD-L1.AAPS J2022
36105215Investigating brain uptake of a non-targeting monoclonal antibody after intravenous and intracerebroventricular administration.Front Pharmacol2022
33298591Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling.Mol Cancer Ther2021
34959386Pharmacokinetics and Pharmacodynamics of T-Cell Bispecifics in the Tumour Interstitial Fluid.Pharmaceutics2021
34862519A Novel Approach for Quantifying the Pharmacological Activity of T-Cell Engagers Utilizing In Vitro Time Course Experiments and Streamlined Data Analysis.AAPS J2021
34326166Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies.J Immunother Cancer2021
34280257Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.Blood2021
34162679Cytokine Release Syndrome By T-cell-Redirecting Therapies: Can We Predict and Modulate Patient Risk?Clin Cancer Res2021
32575160PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse-Type Tenosynovial Giant Cell Tumor.Clin Pharmacol Ther2020
31729169Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer.Clin Transl Sci2020
29090407PKPD modeling of acquired resistance to anti-cancer drug treatment.J Pharmacokinet Pharmacodyn2017
26891981Recent developments in using mechanistic cardiac modelling for drug safety evaluation.Drug Discov Today2016
26496429Influence of molecular size on tissue distribution of antibody fragments.MAbs2016
27638857Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.Mol Cancer Ther2016
27978984Translational PK/PD modeling to increase probability of success in drug discovery and early development.Drug Discov Today Technol2016
27507056First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.Oncotarget2016
27081038Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.Oncotarget2016
25822652Model-based assessment of erlotinib effect in vitro measured by real-time cell analysis.J Pharmacokinet Pharmacodyn2015
26225225Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.CPT Pharmacometrics Syst Pharmacol2015
24898549Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.Cancer Cell2014
24812409Preclinical optimization of MDM2 antagonist scheduling for cancer treatment by using a model-based approach.Clin Cancer Res2014
20484614No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.J Clin Pharmacol2011
19387803Modeling of tumor growth and anticancer effects of combination therapy.J Pharmacokinet Pharmacodyn2009
11955283Aerobic sn-glycerol-3-phosphate dehydrogenase from Escherichia coli binds to the cytoplasmic membrane through an amphipathic alpha-helix.Biochem J2002
  • 1 - 30 of 30

Recommended Authors

Mark A Murakami
Dana-Farber Cancer Institute
Career Start Year 2015
Number of shared co-authors 0
Taher Abbasi
Cellworks Group Inc.
Career Start Year 2011
Number of shared co-authors 0
Nehme El-Hachem
Centre Hospitalier Universitaire Sainte-Justine Research Centre
Career Start Year 2011
Number of shared co-authors 0
Kivilcim Ozturk
Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University
Career Start Year 2010
Number of shared co-authors 0
Hong Xie
Janssen Research & Development LLC
Career Start Year 2009
Number of shared co-authors 0
Marc Hafner
Harvard Medical School
Career Start Year 2009
Number of shared co-authors 2
Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 0
Rajendar K Mittapalli
Pfizer Inc.
Career Start Year 2008
Number of shared co-authors 0
Ahmed Aman
Ontario Institute for Cancer Research, University Avenue
Career Start Year 2007
Number of shared co-authors 0
John F Reilly
Goldfinch Bio Inc.
Career Start Year 2007
Number of shared co-authors 0
Alwin G Schuller
Oncology R&D
Career Start Year 2007
Number of shared co-authors 0
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 4
Paul Hamberg
Franciscus Gasthuis & Vlietland Hospital Rotterdam and Schiedam
Career Start Year 2006
Number of shared co-authors 0
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 2
Pavlos Msaouel
The University of Texas MD Anderson Cancer Center
Career Start Year 2004
Number of shared co-authors 2
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 1
Stephane Ferretti
Novartis Institutes for BioMedical Research
Career Start Year 2003
Number of shared co-authors 0
Mar??a Jos?? Guill??n
Instituto de Investigaciones Biomedicas "Alberto Sols"
Career Start Year 2001
Number of shared co-authors 2
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Salvador Fudio
Clinical Development
Career Start Year 1998
Number of shared co-authors 2
Sunil Sharma
Brody School of Medicine, East Carolina University
Career Start Year 1997
Number of shared co-authors 0
David de Graaf
Syntimmune Inc.
Career Start Year 1995
Number of shared co-authors 0
Lillian L Siu
Princess Margaret Cancer Centre, University Ave
Career Start Year 1995
Number of shared co-authors 1
Sharyn D Baker
Ohio State University
Career Start Year 1994
Number of shared co-authors 0
Cynthia Sung
Health Services and Systems Research, Duke-NUS Medical School
Career Start Year 1990
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
Jan H M Schellens
Department of Pharmaceutical Sciences, Utrecht University
Career Start Year 1987
Number of shared co-authors 1
Mark J Ratain
University of Chicago
Career Start Year 1985
Number of shared co-authors 0
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 3
Paul Workman
The Institute of Cancer Research
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Mehdi Bouhaddou
J. David Gladstone Institutes
Co-authored papers 2
Marc R Birtwistle
Clemson University.
Co-authored papers 2
Li Yu
LIYU Pharmaceutical Consulting LLC, Clemson University
Co-authored papers 2
Hans Clevers
Princess Maxima Center for Pediatric Oncology
Co-authored papers 1
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 1
Martin Schwemmle
Institute of Virology, Medical Center - University of Freiburg
Co-authored papers 1
Arthur J Van De Vyver
Roche Pharma Research & Early Development
Co-authored papers 1
Georg Kochs
Institute of Virology, Freiburg University Medical Center, University of Freiburg
Co-authored papers 1
John Paul Shen
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 1
Emmanuel Raffoux
Universite Paris Diderot
Co-authored papers 1
Sebastian Weigang
Institute of Virology, Freiburg University Medical Center, University of Freiburg
Co-authored papers 1
James M Gallo
Co-authored papers 1
Release 1.2